Market Outlook:

The Interventional Oncology market size is poised to reach USD 2,354.54 Million by 2024, with a projected escalation to USD 2,761.99Million by 2032, reflecting a compound annual growth rate (CAGR) of 9.1% during the forecast period (2024-2032). 

The interventional oncology market is expanding because of three main drivers consisting of the increasing worldwide cancer prevalence together with the rise in minimally invasive procedure preferences along with continuous technical developments. The development of poor resectable tumor cancers in the liver, lungs, kidneys, and colon drives medical practices in interventional oncology through procedures such as transarterial chemoembolization (TACE) and transcatheter arterial radioembolization (TARE) and percutaneous ablation. Better acceptance will arise from the growing preference for out-patient or day-care medical procedures because these services offer both economic efficiencies and increased convenience.

Market Dynamics:

Driver:

Patient number growth in cancer cases drives market success in interventional oncology. Multiple reasons including age effects and environmental dangers result in a growth of cancer cases worldwide which continues to rise yearly. Most liver cancer cases along with lung cancer start as advanced stages which make traditional surgical procedures ineffective because patient conditions no longer allow standard treatment methods. There are more patients who need the less invasive image-guided treatments performed by interventional oncologists who treat cancer and provide solutions for better quality of life and possible cures. Oncology interventions include TACE treatments for feeding arteries plus TARE using radiation beads in addition to performing ablation procedures. These methods now help treat cancer patients who have tumors that doctors cannot remove fully and when the disease has spread.

Restraint:

Equipment expenses and advanced tools create main limits for interventional oncology expansion. In particular, some treatments involving the disease under this treatment procedure are more sophisticated; thus, for TACE, TARE, and percutaneous ablation, for example, involve Yttrium-90 and a wide array of specialized catheters and embolic agents coupled with imaging technology in top shape, adding greatly to its expensive costs due to production and upscaling and other means.In addition, the highly specialized interventional radiologists and auxiliary staff increase the costs of the procedure. Medical facilities face limited interventional oncology capacity because they lack sufficient staff due to budget problems and need for essential equipment.

Opportunity:

Interventional oncology benefits from new market growth in emerging nations since these economies develop medical infrastructure rapidly to address high cancer rates through advanced healthcare treatments in Asia-Pacific and other developing regions. Healthcare facilities in these areas get complete upgrades along with better medical technologies and their associated systems. The fast-growing number of aging individuals who face lifestyle changes and rising rates of weight problems combines with greater smoking numbers and more people infected with hepatitis to create significant cancer burden demands more effective and convenient treatment methods. The field of interventional oncology offers benefits for healthcare transformation because it avoids major surgical methods and patients need reduced recovery time and lower treatment expenses.

Key Players:

• Siemens Healthineers AG (Varian) (US)
• Medtronic (Ireland)
• Boston Scientific Corporation (US)
• Terumo Corporation (Japan)
• Merit Medical Systems (US)
• Johnson & Johnson MedTech (Ethicon) (US)
• Stryker (US)
• Teleflex Incorporated (US)
• AngioDynamics (US)
• Cook (US)
• IceCure Medical (Israel)
• Olympus Corporation (Japan)
• IMBiotechnologies Ltd (Canada)
• MedWaves Inc. (US)
• Minimax Medical Limited (China)
• ABK Biomedical Inc. (Canada)
• RF Medical Co., Ltd. (South Korea)
• Profound Medical (Canada)
• Surgnova (China)
• STARmed America (US)

Recent Development:

• In December 2024, AngioDynamics added new treatment options and enhanced patient well-being when they received U.S. Food and Drug Administration approval to use the NanoKnife system for destroying prostate tissue.

• In December 2024, Siemens Healthineers collaborated with AP-HP to create new medical solutions for better patient healthcare. Through this agreement Siemens Healthineers and AP-HP expand their medical technologies to maintain high quality healthcare for patients and adjust their approach to France's changing healthcare system.

Segment Insights:

By Devices & Consumables

Today embolization devices shape the interventional oncology market because they allow minimally invasive cancer treatment methods that bring better results than regular surgery. The method these devices apply shuts down blood flow to tumors so the cells starve from missing their oxygen and nutritional supplies. TACE and SIRT become increasingly popular because studies show effective results from treating nonoperative liver cancer cases. Doctors will use drug-impregnated beads and radioactive spheres to make embolic treatments better focused and work faster. Hospital patients worldwide choose minimally invasive treatment as the cancer burden grows fast which makes demand for embolization devices skyrocket.

By End-user

The biggest portion of the market belongs to liver cancer because more people develop this condition and die from it while needing better and less invasive treatment solutions. Hepatocellular carcinoma makes up most liver cancer cases and develops because of prolonged hepatitis B/C infection, heavy alcohol usage, and more non-alcoholic fatty liver disease cases. Interventional oncology uses specific treatment methods such as transarterial chemoembolization, transarterial radioembolization and percutaneous ablation methods because research proves their benefit for unresectable liver cancer patients. These treatment methods are successful in controlling tumors at a specific point because they reduce side effects throughout the body and help patients live better than standard chemotherapy.

Regional Insights:

Hundreds of advanced medical facilities together with intense patient desire make North America hold the number-one position in interventional oncology. The United States holds the leading position in the market because it maintains modern comprehensive facilities where interventional radiology procedures are delivered. The growing incidence of liver, lung, and kidney cancers-the main areas for interventional oncology-provides significant impetus for less invasive treatments such as TACE, TARE, and thermal ablation. The healthcare system will grow with new medical professionals who deliver high-level interventional radiology and cancer treatments.

Segmentation:

By Devices & Consumables

• RF
• Cicrowave
• Cryoablation
• Embolization

By Procedures                         

• Thermal Ablation
• Non-Thermal Ablation
• TACE
• TARE
• TAE

By Cancer

• Liver
• Lung
• Kidney

By End-use

• Hospital
• Specialty Clinic

By Region

North America

• USA

• Canada

• Mexico

Europe

• France

• UK

• Spain

• Germany

• Italy

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• South Korea

• Rest of Asia Pacific

Middle East & Africa

• GCC

• South Africa

• Rest of the Middle East & Africa

South America

• Brazil

• Argentina

• Rest of South America

What to Expect from Industry Profile?

1. Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the Interventional Oncology market in the world.

2. Use the PORTER’s Five Forces analysis to determine the competitive intensity and therefore market attractiveness of the Global Interventional Oncology market.

3. Leading company profiles reveal details of key Interventional Oncology market players’ global operations, strategies, financial performance & recent developments.

4. Add weight to presentations and pitches by understanding the future growth prospects of the Global Interventional Oncology market with forecast for the decade by both market share (%) & revenue (USD Million).

FAQ’s

1) What are the major factors driving the growth of the Global Interventional Oncology Market?

• Innovations in minimally invasive procedures, such as ablation and embolization techniques is expanding applications of Interventional Oncology across various industries.

2) What would be the CAGR of the Global Interventional Oncology Market over the forecast period?

• The Global Interventional Oncology Market is poised to grow at a CAGR of 9.1% from 2024 to 2032.

3) Which region will provide more business opportunities for the growth of the Global Interventional Oncology Market in the future?

• The North America region is expected to create more opportunities in the market.

4) Who are the major players dominating the Global Interventional Oncology Market?

• Siemens Healthineers AG (Varian) (US), Medtronic (Ireland), Boston Scientific Corporation (US), Terumo Corporation (Japan), Merit Medical Systems (US), Johnson & Johnson MedTech (Ethicon) (US), Stryker (US), Teleflex Incorporated (US), AngioDynamics (US), Cook (US), IceCure Medical (Israel), Olympus Corporation (Japan).

5) What are the segments in the Global Interventional Oncology Market?

• By Procedures, By End-user, By Devices & Consumables, By Cancer are the industry key segments considered for research study.

6) What is the estimated market revenue for the Global Interventional Oncology Market in 2032?

• The estimated revenue for the Global Interventional Oncology Market in 2032 is USD 2,761.99Million.